Valuation: Dogwood Therapeutics, Inc.

Market Cap 48.43M 42.47M 39.21M 36.24M 68.68M 4.64B 70.06M 471M 183M 2.27B 182M 178M 7.88B P/E 2026 *
-2.46x
P/E 2027 * -2.2x
Enterprise Value 48.43M 42.47M 39.21M 36.24M 68.68M 4.64B 70.06M 471M 183M 2.27B 182M 178M 7.88B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
26.64%
Yield 2026 *
-
Yield 2027 * -
1 day-5.56%
1 week-9.33%
Current month-15.53%
1 month-6.85%
3 months-29.90%
6 months-56.83%
Current year-67.31%
1 week 1.28
Extreme 1.28
1.61
1 month 1.28
Extreme 1.28
1.8
Current year 1.28
Extreme 1.28
4.34
1 year 1.28
Extreme 1.28
9.5
3 years 1.28
Extreme 1.28
60.5
5 years 1.28
Extreme 1.28
227.77
10 years 1.28
Extreme 1.28
417.75
Date Insider Type Main position Quantity % Market Cap.
06-15Free

Director

16,800 0.0505%
06-15Free

Director

16,800 0.0505%
06-15Free

Director

16,800 0.0505%
Change 5-day change 1-year change 3-year change Capi.($)
-3.47%-9.33%-71.90%-96.42% 48.43M
-1.53%+0.78%+72.33%+127.47% 57.72B
-2.45%-7.32%+65.23%+83.15% 52.65B
+2.49%+8.07%+20.27%+466.81% 24.46B
-1.85%-1.25%-16.94%-13.66% 23.84B
-3.05%+3.06%+42.36%-5.66% 19.28B
-0.24%+5.11%+38.76%-25.95% 17.8B
+2.34%+14.18%+220.96%+380.99% 17.29B
-6.73%+9.90%+36.04% - 15.28B
-2.40%+2.97%+27.69%+191.35% 14.35B
Average -1.91%+3.62%+43.48%+123.12% 24.27B
Weighted average by Cap. -1.49%+2.70%+57.57%+138.86%

Financials

2026 *2027 *
Net sales - -
Net income -19.79M -17.36M -16.02M -14.81M -28.06M -1.89B -28.63M -193M -74.84M -927M -74.31M -72.68M -3.22B -24.52M -21.51M -19.85M -18.35M -34.78M -2.35B -35.47M -239M -92.74M -1.15B -92.08M -90.06M -3.99B
Net Debt - -
Logo Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc. is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).
Employees
8
Date Price Change Volume
26-07-08 US$1.390 -3.47% 62,095
26-07-07 US$1.440 +4.35% 225,138
26-07-06 US$1.380 -7.38% 271,992
26-07-02 US$1.490 -0.67% 107,758
26-07-01 US$1.500 -6.83% 135,901
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.440USD
Average target price
14.00USD
Spread / Average Target
+872.22%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DWTX Stock